884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.
Saved in:
| Title: | 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. |
|---|---|
| Authors: | Teichner, Paula1 (AUTHOR), Cutrell, Amy1 (AUTHOR), D'Amico, Ronald1 (AUTHOR), Dorey, David2 (AUTHOR), Griffith, Sandy1 (AUTHOR), Harrington, Conn M1 (AUTHOR), Huang, Jenny2 (AUTHOR), Hudson, Krischan J1 (AUTHOR), Margolis, David1 (AUTHOR), Mrus, Joseph1 (AUTHOR), Polli, Joseph1 (AUTHOR), Spreen, William1 (AUTHOR), Williams, Peter3 (AUTHOR), Solingen-Ristea, Rodica Van3 (AUTHOR), Shaefer, Mark S4 (AUTHOR) |
| Source: | Open Forum Infectious Diseases. 2019 Supplement, Vol. 6, pS20-S20. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
